Apollo Endosurgery Inc (LPTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, discovers and develops monoclonal antibodies that target bioactive lipids. It develops lipidomic-based therapeutic antibodies that target bioactive signaling lipids to treat a wide range of human diseases. The company’s pipeline product candidates include iSONEP, indicated for age-related macular degeneration (AMD), retinal pigment epithelium (RPE) detachment and other retinal diseases; ASONEP indicated for various types of cancer; and Lpathomab indicated for fibrosis, spinal cord injury, traumatic brain injury, neuropathic pain and cancer. The company's proprietary platform technology is applied in various therapeutic areas such as cancer, pain, asthma, inflammation, sepsis and others. The company also provides contract research and manufacturing services to other pharmaceutical companies. Apollo Endo is headquartered in San Diego, California, the US.
Apollo Endosurgery Inc Key Recent Developments
Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer
Jan 19, 2016: Leading Medical Device Companies Select Brainshark to Drive Sales Productivity
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Section 1 - About the Company 5
Apollo Endosurgery Inc - Key Facts 5
Apollo Endosurgery Inc - Key Employees 6
Apollo Endosurgery Inc - Key Employee Biographies 7
Apollo Endosurgery Inc - Major Products and Services 8
Apollo Endosurgery Inc - Pharmaceutical Pipeline Products Data 9
Apollo Endosurgery Inc, Pipeline Products by Therapy Area 9
Apollo Endosurgery Inc, Pipeline Products by Development Phase 10
Apollo Endosurgery Inc - History 11
Apollo Endosurgery Inc - Company Statement 13
Apollo Endosurgery Inc - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 17
Apollo Endosurgery Inc - Business Description 17
Apollo Endosurgery Inc - Corporate Strategy 18
Apollo Endosurgery Inc - SWOT Analysis 19
SWOT Analysis - Overview 19
Apollo Endosurgery Inc - Strengths 19
Apollo Endosurgery Inc - Weaknesses 20
Apollo Endosurgery Inc - Opportunities 21
Apollo Endosurgery Inc - Threats 22
Apollo Endosurgery Inc - Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Apollo Endosurgery Inc, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 33
Jan 19, 2016: Leading Medical Device Companies Select Brainshark to Drive Sales Productivity 34
Section 6 – Appendix 35
Methodology 35
Ratio Definitions 35
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
Apollo Endosurgery Inc, Key Facts 5
Apollo Endosurgery Inc, Key Employees 6
Apollo Endosurgery Inc, Key Employee Biographies 7
Apollo Endosurgery Inc, Major Products and Services 8
Apollo Endosurgery Inc, Number of Pipeline Products by Therapy Area 9
Apollo Endosurgery Inc, Number of Pipeline Products by Development Stage 10
Apollo Endosurgery Inc, History 11
Apollo Endosurgery Inc, Subsidiaries 16
Apollo Endosurgery Inc, Key Competitors 23
Apollo Endosurgery Inc, Ratios based on current share price 24
Apollo Endosurgery Inc, Annual Ratios 25
Apollo Endosurgery Inc (Cont...1), Annual Ratios 26
Apollo Endosurgery Inc, Interim Ratios 28
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Apollo Endosurgery Inc, Recent Deals Summary 32
Currency Codes 35
Capital Market Ratios 35
Equity Ratios 36
Profitability Ratios 36
Cost Ratios 37
Liquidity Ratios 37
Leverage Ratios 37
Efficiency Ratios 38
List of Figures
Apollo Endosurgery Inc, Pipeline Products by Therapy Area 9
Apollo Endosurgery Inc, Pipeline Products by Development Phase 10
Apollo Endosurgery Inc, Performance Chart (2011 - 2015) 27
Apollo Endosurgery Inc, Ratio Charts 29
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 31